Correlation analysis for alterations of intestinal flora in hepatocellular carcinoma patients: combinatorial detection of Coriobacterium, Atopobium, Coprococcus and Veillonella dispar may be a new method for HCC diagnosis.

Introduction. Hepatocellular carcinoma (HCC) is one of the most common malignant tumours in the world. Due to the characteristics of low early diagnosis rate, high malignancy and rapid progression, the majority of diagnosed patients are in the middle or late stage. Accumulating evidence reveals that intestinal flora imbalance will aggravate HCC by disturbing immune regulation, especially interleukin expression. Therefore, intestinal flora-based methods have the potential to be new diagnostic or therapeutic methods for HCC.Hypothesis. Compositions of intestinal florae were different between HCC patients and healthy people. Further, intestinal florae may alleviate or aggravate HCCs.Methods. To determine which intestinal florae and interleukin aggravate HCCs, we studied the differences in intestinal florae composition and interleukin (IL) indices between HCC patients and healthy people. A total of 64 HCC patients and 24 healthy people were recruited, and their fresh stool samples and serum samples were collected for 16S rRNA sequencing and metabolite index measurement.Results. Data showed that 484 operational taxonomic units (OTUs) and 476 OTUs were detected in the HCC and control groups, respectively. From the phylum level to the species level, 5, 6, 10, 15, 23 and 19 colonies showed differential abundance between the HCC group and healthy people. Moreover, interleukin-6 expression and interleukin-10 expression were significantly different between two groups. Of note, differences of Coriobacterium, Atopobium and Coprococcus at genus level and Veillonella dispar at species level in two groups were significantly related to IL-6 and IL-10.Conclusion. The abundance of intestinal florae in the HCC group was different from the control group. Additionally, combinatorial detection of Coriobacterium, Atopobium and Coprococcus at genus level and V. dispar at species level may be a new method for HCC diagnosis.

[1]  P. Bork,et al.  Enterotypes of the human gut mycobiome , 2022, bioRxiv.

[2]  H. Akkız.  The Gut Microbiome and Hepatocellular Carcinoma , 2021, Journal of Gastrointestinal Cancer.

[3]  E. Y. Kim,et al.  Relationship of the lung microbiome with PD-L1 expression and immunotherapy response in lung cancer , 2021, Respiratory Research.

[4]  O. Coker.  Non‐bacteria microbiome (virus, fungi, and archaea) in gastrointestinal cancer , 2021, Journal of gastroenterology and hepatology.

[5]  Xiao-dong Zhu,et al.  Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview , 2021, Frontiers in Oncology.

[6]  P. Chu,et al.  Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma , 2021, Cancers.

[7]  Qiushui He,et al.  Dysbiosis of Gut Microbiota Promotes Hepatocellular Carcinoma Progression by Regulating the Immune Response , 2021, Journal of immunology research.

[8]  T. Salvatore,et al.  HCC and Molecular Targeting Therapies: Back to the Future , 2021, Biomedicines.

[9]  Xu-zhi Wan,et al.  Eicosapentaenoic and docosahexaenoic acids attenuate hyperglycemia through the microbiome-gut-organs axis in db/db mice , 2021, Microbiome.

[10]  Miao Wu,et al.  The Role of Gut Microbiota in Tumor Immunotherapy , 2021, Journal of immunology research.

[11]  J. Gallon,et al.  Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma , 2021, Molecular oncology.

[12]  W. Dai,et al.  The gut microbiome-bile acid axis in hepatocarcinogenesis. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[13]  P. Viatour,et al.  Hepatocellular carcinoma: old friends and new tricks , 2020, Experimental & Molecular Medicine.

[14]  F. Cobo,et al.  Bacteremia caused by Veillonella dispar in an oncological patient , 2020, Anaerobe.

[15]  Z. Lv,et al.  Alterations of Gut Microbiome and Metabolite Profiling in Mice Infected by Schistosoma japonicum , 2020, Frontiers in Immunology.

[16]  Xiao Jianhua,et al.  Systematic Review of the Roles of Interleukins in Hepatocellular Carcinoma. , 2020, Clinica chimica acta; international journal of clinical chemistry.

[17]  İlkay Yılmaz,et al.  Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: A randomized controlled trial. , 2020, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[18]  A. Dhawan,et al.  Interleukin 10: the critical role of a pleiotropic cytokine in food allergy. , 2020, Allergologia et immunopathologia.

[19]  Y. Morine,et al.  Hepatic Stellate Cells Contribute to the Tumor Malignancy of Hepatocellular Carcinoma Through the IL-6 Pathway , 2020, AntiCancer Research.

[20]  R. Schwabe,et al.  Gut microbiome in HCC - Mechanisms, diagnosis and therapy. , 2020, Journal of hepatology.

[21]  Q. Ou,et al.  Gut microbiota dysbiosis in patients with hepatitis B virus–induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma , 2020, Journal of viral hepatitis.

[22]  W. Shi,et al.  Saccharibacteria (TM7) in the Human Oral Microbiome , 2019, Journal of dental research.

[23]  Min Yang,et al.  Interleukin 10 Gene-Modified Bone Marrow-Derived Dendritic Cells Attenuate Liver Fibrosis in Mice by Inducing Regulatory T Cells and Inhibiting the TGF-β/Smad Signaling Pathway , 2019, Mediators of inflammation.

[24]  S. Khakoo,et al.  Activity of IL-12/15/18 primed natural killer cells against hepatocellular carcinoma , 2018, Hepatology International.

[25]  J. Shimizu,et al.  Propionate-producing bacteria in the intestine may associate with skewed responses of IL10-producing regulatory T cells in patients with relapsing polychondritis , 2018, PloS one.

[26]  Toshio Tanaka,et al.  Interleukin (IL-6) Immunotherapy. , 2018, Cold Spring Harbor perspectives in biology.

[27]  Yaming Li,et al.  Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition) , 2018, Liver Cancer.

[28]  E. Hsiao,et al.  The Microbiome and Host Behavior. , 2017, Annual review of neuroscience.

[29]  R. Schwabe,et al.  The gut microbiome and liver cancer: mechanisms and clinical translation , 2017, Nature Reviews Gastroenterology &Hepatology.

[30]  O. Lushchak,et al.  Association between body mass index and Firmicutes/Bacteroidetes ratio in an adult Ukrainian population , 2017, BMC Microbiology.

[31]  Ali Keshavarzian,et al.  Colonic bacterial composition in Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[32]  Cara L. Wilhelm,et al.  Proteobacteria-specific IgA regulates maturation of the intestinal microbiota , 2014, Gut microbes.

[33]  L. Tang,et al.  Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. , 2012, Journal of hepatology.

[34]  M. H. Fernandes,et al.  Marine Cyanobacteria Compounds with Anticancer Properties: A Review on the Implication of Apoptosis , 2012, Marine drugs.

[35]  Liang Tang,et al.  Endotoxin accumulation prevents carcinogen‐induced apoptosis and promotes liver tumorigenesis in rodents , 2010, Hepatology.

[36]  Y. Hoshida,et al.  Hepatocellular Carcinoma: Translational Precision Medicine Approaches , 2019, Molecular and Translational Medicine.

[37]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[38]  J. Nielsen,et al.  Molecular Systems Biology Peer Review Process File the Gut Microbiota Modulates Host Amino Acid and Glutathione Metabolism in Mice Editor: Maria Polychronidou Transaction Report: Response to Reviewers , 2022 .

[39]  S. Rosini,et al.  Solitary plasmacytoma of the tonsillar site associated with actinomyces infection: the possible role of IL-6. , 2012, Journal of biological regulators and homeostatic agents.